临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
IACS-13909
中文名称:1-[3-(2,3-二氯苯基)-1H-吡唑[3,4-b]吡嗪-6-基]-4-甲基哌啶-4-胺
CAS号:2160546-07-4
分子式: C17H18Cl2N6 分子量: 377.27
产品形式: Free Base
研发状态: Recruiting
研发用途: Advanced Solid Tumor; Advanced or Metastatic Non-small Cell Lung Cancer
研究机构: LianBio LLC
研发日期: October 18 2022
研发阶段: Phase 1
IACS-13909 is a specific and potent allosteric inhibitor of SHP2 (Src homology 2 domain-containing phosphatase) that suppresses signaling through the MAPK pathway.
Sodium dichloroacetate (DCA)
中文名称:二氯乙酸钠
CAS号:2156-56-1
分子式: C2HCl2O2.Na 分子量: 150.92
产品形式: sodium salt
研发状态: Not yet recruiting
研发用途: Stroke; Traumatic Brain Injury; Knee Osteoarthritis; Breast Cancer
研究机构: Tan Tock Seng Hospital; Rehabilitation Research Institute of Singapore (RRIS); Woodlands Health (WH)
研发日期: Dec-23
研发阶段: --
Sodium dichloroacetate (DCA, Dichloroacetic acid, bichloroacetic acid, BCA), a specific inhibitor of pyruvate dehydrogenase kinase (PDK) with IC50 values of 183 and 80 μM for PDK2 and PDK4 respectively, has been shown to derepress Na+-K+-2Cl- cotransporter and a mitochondrial potassium-ion channel axis. Sodium dichloroacetate increases reactive oxygen species (ROS) generation, triggers apoptosis in cancer cells, and inhibits tumor growth.
Clindamycin HCl
中文名称:盐酸克林霉素
CAS号:21462-39-5
分子式: C18H33ClN2O5S.HCl 分子量: 461.44
产品形式: Hydrochloride
研发状态: Completed
研发用途: Acne Vulgaris
研究机构: Jinnah Postgraduate Medical Centre
研发日期: August 1 2022
研发阶段: Phase 2
Clindamycin HCl inhibits protein synthesis by acting on the 50S ribosomal, used for the treatment of bacterial infections.
Cirtuvivint
CAS号:2143917-62-6
分子式: C24H25N7O 分子量: 427.50
产品形式: free base
研发状态: Active not recruiting
研发用途: Solid Tumor Adult
研究机构: Biosplice Therapeutics Inc.
研发日期: November 6 2017
研发阶段: Phase 1
Cirtuvivint (SM08502) is a potent and orally active inhibitor of CDC-like kinase (CLK) and a DYRK (dual-specificity tyrosine kinase) that targets mRNA splicing and is optimized for Wnt pathway inhibition. Cirtuvivint inhibits serine and arginine-rich splicing factor (SRSF) phosphorylation and disrupts spliceosome activity. Cirtuvivint can be used for solid tumor research.
ABBV-744
CAS号:2138861-99-9
分子式: C28H30FN3O4 分子量: 491.55
产品形式: Free Base
研发状态: Active not recruiting
研发用途: Myelofibrosis (MF)
研究机构: AbbVie
研发日期: November 11 2020
研发阶段: Phase 1
ABBV-744 is a BDII-selective BET bromodomain inhibitor that inhibits BRD2, BRD3 and BRD4. It is developed for treating AML and cancers.
RITA (NSC 652287)
中文名称:5,5'-(2,5-呋喃二基)二-2-噻吩甲醇
CAS号:213261-59-7
分子式: C14H12O3S2 分子量: 292.37
产品形式: free base
研发状态: Completed
研发用途: Multiple Myeloma; Solitary Plasmacytoma; Amyloidosis; Chronic Myeloid Leukemia; Chronic Lymphocytic Leukemia; T Cell Non-Hodgkin Lymphoma; Lymphocytic Lymphoma; Hodgkin Lymphoma; B-cell Non Hodgkin Lymphoma; Acute Myeloid Leukemia; Myelodysplasia; Chronic Myeloproliferative Disorder; Treatment Adherence; Treatment Adherence and Compliance
研究机构: Advice Pharma Group srl
研发日期: June 4 2022
研发阶段: Not Applicable
RITA (NSC 652287) induces both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks, and also inhibits MDM2-p53 interaction by targeting p53.
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
